icon
Image from Google Jackets
Image from OpenLibrary

The right price : a value-based prescription for drug costs / Peter J. Neumann, Joshua T. Cohen, and Daniel A. Ollendorf.

By: Contributor(s): Publisher: New York, NY : Oxford University Press, [2021]Description: xv, 255 pages : illustrations ; 24 cmContent type:
  • text
Media type:
  • unmediated
Carrier type:
  • volume
ISBN:
  • 9780197512883
  • 9780197512876
Subject(s): Additional physical formats: Online version:: The right priceDDC classification:
  • 368.38/24 23 N492
Contents:
The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.
Summary: The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these treatments seem to offer modest gains in life expectancy or lack such evidence at all. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million dollar price tags, the need for sensible drug pricing and coverage policies will intensify.
Item type: كتاب
Tags from this library: No tags from this library for this title.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Status Notes Date due Barcode
كتاب كتاب Central Library المكتبة المركزية 368.3824 N492 (Browse shelf(Opens below)) Available قاعة الكتب 48448

Includes bibliographical references and index.

The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.

The pharmaceutical industry and its pricing methods provide an inviting target, easy to disparage and caricature. Even after accounting for discounts and rebates, average prices of leading brand-name drugs in the US are two to four times higher than they are in Canada, Japan, and many European countries. US per capita spending on prescription drugs is more than twice the level in the United Kingdom. Prices for most new cancer drugs now exceed $100,000 per patient per year of treatment, despite the fact that many of these treatments seem to offer modest gains in life expectancy or lack such evidence at all. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million dollar price tags, the need for sensible drug pricing and coverage policies will intensify.